Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired

Related Experiment Video

Updated: Oct 31, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

W D Creery1, A Hashmi, J S Hutchison

  • 1Department of Pediatrics, University of Ottawa, Ontario, Canada.

Pediatric Pulmonology
|January 4, 1998
PubMed

Insights

Pneumocystis pneumonia (PCP) can cause acute respiratory failure in children with HIV. Bovine lipid extract surfactant improved lung function in two infants with PCP and acute respiratory distress syndrome (ARDS).

Area of Science:

  • Pediatric pulmonology
  • Infectious diseases
  • Critical care medicine

Background:

  • Pneumocystis pneumonia (PCP) is a severe respiratory illness in children with HIV.
  • PCP can lead to acute respiratory distress syndrome (ARDS) by disrupting lung surfactant.
  • Current treatments for PCP/ARDS in children have limitations.

Observation:

  • Two infants with acquired immunodeficiency syndrome (AIDS)-related PCP/ARDS presented with acute respiratory failure.
  • Pulmonary function was assessed before and after intervention.
  • The infants received bovine lipid extract surfactant.

Findings:

  • Administration of bovine lipid extract surfactant led to improved pulmonary function in both infants.
  • This suggests a potential benefit of exogenous surfactant in managing PCP/ARDS.
  • The study highlights the role of surfactant dysfunction in PCP pathogenesis.

Implications:

  • Bovine lipid extract surfactant may be a viable adjunctive therapy for pediatric PCP/ARDS.
  • Further research is warranted to confirm efficacy and optimal dosing.
  • This approach could improve outcomes for critically ill, HIV-infected children.

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.